Haleon plc Reports Board Changes
Ticker: HLNCF · Form: 6-K · Filed: Dec 5, 2024 · CIK: 1900304
Sentiment: neutral
Topics: board-changes, reporting
TL;DR
Haleon plc filed a 6-K on Dec 5, 2024, reporting board changes. Details are in Exhibit 99.1.
AI Summary
Haleon plc announced board changes on December 5, 2024. The filing, a Form 6-K, details these changes as part of its regular reporting for the month of December 2024. No specific individuals or financial figures related to these changes were detailed in the provided excerpt.
Why It Matters
Board changes can signal shifts in company strategy, governance, or leadership, impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing is a routine report of board changes and does not contain information that would immediately impact the company's financial standing or operations.
Key Players & Entities
- Haleon plc (company) — Registrant
- DRVW 2022 Ltd (company) — Former company name
FAQ
What specific board changes were announced by Haleon plc on December 5, 2024?
The provided excerpt indicates that Exhibit 99.1, titled 'Board Changes', was filed on December 5, 2024, but the specific details of the changes are not included in this excerpt.
What is the filing type and accession number for this report?
The filing type is Form 6-K, and the accession number is 0001654954-24-015178.
When was Haleon plc formerly known as?
Haleon plc was formerly known as DRVW 2022 Ltd, with a date of name change on December 17, 2021.
What is Haleon plc's primary business classification according to the SEC?
Haleon plc is classified under STANDARD INDUSTRIAL CLASSIFICATION: PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844].
Where is Haleon plc's principal executive office located?
Haleon plc's principal executive offices are located at Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 11.5 · Accepted 2024-12-05 06:50:36
Filing Documents
- a9659o.htm (6-K) — 22KB
- a9659o000.jpg (GRAPHIC) — 3KB
- 0001654954-24-015178.txt ( ) — 28KB
From the Filing
CHANGES a9659o UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of December 2024   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number   Description   99.1 05 December 2024 - Board Changes           99.1         Haleon plc: Board Changes     5 December 2024:   Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the following changes to the Board.   Following the reduction of Pfizer Inc.'s shareholding in Haleon plc below 20%, and in line with the Pfizer Relationship Agreement with Haleon plc, David Denton, Non-Executive Director and representative of Pfizer Inc., stepped down from the Board on 4 December 2024.   Bláthnaid Bergin has been appointed as an independent Non-Executive Director and will join the Haleon Board on 24 February 2025.   Bláthnaid Bergin brings financial leadership and strategic planning experience from a variety of consumer-facing businesses. Bláthnaid is currently the Chief Financial Officer of J Sainsbury plc, where she has played a pivotal role in driving the company's financial strategy and operational efficiency initiatives. Prior to joining Sainsbury's, Bláthnaid held senior finance leadership and international positions at Aviva, RSA and GE working across Europe, Asia and Australia. She is a Chartered Accountant. Bláthnaid was previously Non-Executive Director, Chair of the Audit Committee and Senior Independent Director for Artemis Alpha Investment Trust.   Sir Dave Lewis, Haleon's Chair commented:  "On behalf of the Board, I would like to thank Dave for his insights and contributions to the Board's discussions. We wish him all the very best for the future. I would like to welcome Bláthnaid to Haleon. With her strong track record of financial leadership and transformation from multiple consumer-facing businesses, Bláthnaid brings a wealth of relevant skills and experience to the Board."   The Company confirms that there is no further information to be disclosed under the requirements of UKLR 6.4.6R and 6.4.8R.   Amanda Mellor   Company Secretary     About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .              SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: December 05, 2024 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary